Categories: Uncategorized

Glenmark Pharma gets permission from U.S. FDA for Tacrolimus Capsules

Glenmark Pharmaceuticals gets final approval by the United States Food & Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, and 5 mg, Glenmark said in the regulatory filling. The approved version is 1mg and 5 mg the generic version of Prograf Capsules 0.5 mg, 1 mg, and 5 mg which is of Astellas Pharm US.

These capsules are used as immunosuppressants to prevent human immune system for rejecting liver, kidney and heart transplants.  

According to IQVIA sales data for the 12 mh period ending September 2020 , the Prograf Capsules , 0.5 mg , I mg and 5 mg Market achieved annual sales of approximately $286.8 million.

Glenmark said its current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending for approval with U.S.FDA. 

Medically Speaking Team

Recent Posts

India’s Silent Crisis: 20 Crore Affected by Hypertension

Hypertension, or high blood pressure, has become a silent but deadly crisis in India. The…

16 hours ago

Neuralink’s Breakthrough: Brain Chip Successfully Implanted in Third Patient

Elon Musk's Neuralink has made groundbreaking strides in its mission to integrate brain-computer interface (BCI)…

17 hours ago

Breathing Danger: How Long-Term Air Pollution Impacts Your Health

Air pollution, a silent but pervasive environmental hazard, is increasingly impacting human health worldwide. Long-term…

17 hours ago

Spot the Fakes: Protect Your Health from Counterfeit Medicines

Fake Medicine: Did you know that fake medicines can cause serious damage to your body's…

17 hours ago

Battle Surgical Site Infections: Causes, Symptoms & Prevention Unveiled!

Surgical Site Infection: In India, the rate of infections after surgery is rapidly increasing. Surgical…

18 hours ago

ICMR Study: Surgical Infections in India Higher Than Global Standards

A recent study conducted by the Indian Council of Medical Research (ICMR) reveals concerning insights…

2 days ago